A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout. | A U.S. federal court on Friday shot down Bristol Myers Squibb’s motion to dismiss an investor lawsuit connected to its $74 billion Celgene buyout.
